750P Phase I Safety and Efficacy of Brenetafusp, a PRAME × CD3 ImmTAC T Cell Engager, in Platinum Resistant Ovarian Cancer (PROC) C. Friedman,A. De Burgh Williams,J.S. Lopez,K. Ouali,M.R. Middleton,F. Thistlethwaite,O. Hamid,B. Izar,V. Moreno Garcia,M.L. Johnson,D. Davar,J. Martin-Liberal,P. Roxburgh,K.N. Moore,D. Olson,S. Rottey, P.B. Kirk, Y. Yuan,S. Marshall,O. Yeku
原文链接
分享
引用
